

administering an effective amount of growth hormone or a functionally equivalent analog thereof to a patient in need of such treatment.

33. (New) The method according to Claim 32, wherein said CNS damage affects the oligodendroglia, astroglia, and/or neuronal cells.

34. (New) The method according to Claim 32, wherein said CNS damage affects non-cholinergic neuronal cells, cholinergic neuronal cells, or glial cells.

35. (New) The method according to Claim 32, wherein said CNS damage is neural cell loss.

36. (New) The method according to Claim 32, wherein said CNS damage is caused by hypoxic injury, ischemic injury, and/or traumatic injury.

37. (New) The method according to Claim 32, wherein said medicinal product is formulated for intravenous infusion, intramuscular injection or subcutaneous injection.

38. (New) The method according to Claim 32, wherein said medicinal product is formulated so that the active substance will pass into the ventricles of the patient's brain when it is administered to a patient.

Alced

003300-782

39. (New) The method according to Claim 32, wherein said medicinal product is formulated so that the active substance will pass into the cerebrospinal fluid of the patient when it is administered to a patient.

40. (New) A method for the treatment of an abnormal condition affecting the central nervous system, wherein said abnormal condition is the consequence of axonal damage caused by concussion, axonal damage caused by head trauma, axonal damage caused by small vessel disease in the CNS, damage to the spinal cord after disease and/or trauma comprising administering an effective amount of a substance to a patient whereupon administration of said substance will lead to a decreased concentration of growth hormone or a functionally equivalent analog thereof.

41. (New) The method according to Claim 40, wherein said substance is a negatively regulating growth hormone binding protein, a functionally equivalent analogous thereof, an antibody against growth hormone, a biologically active growth hormone receptor inhibitor, and/or an inhibitor of endogenous growth hormone release.

42. (New) A method of propagating progenitor cells, stem cells and/or cells derived from said cells by administration of an effective amount of growth hormone or a functionally equivalent analogue thereof to stem cells, progenitor cells, neurons astroglial cells and/or oligodendrocytes in vitro.

43. (New) A method of inducing lineage determination or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglia cells from progenitor cells or stem cells in, or derived from, the central or peripheral nervous system in a patient, wherein a pharmaceutically effective amount of growth hormone or a functionally equivalent analogue thereof is administered to a patient in need thereof.

44. (New) A method according to Claim 43, for treatment of an abnormal condition affecting the nervous system of a patient.

45. (New) A method according to Claim 44, wherein said condition affects the oligodendroglia, astroglia, and/or neuronal cells.

46. (New) A method according to Claim 44, wherein said condition affects the non-cholinergic neuronal cells, cholinergic neuronal cells, or glial cells.

47. (New) A method according to Claim 44, wherein said condition is a CNS damage or deficit.

48. (New) A method according to Claim 47, wherein said condition is neural cell loss.

49. (New) A method according to Claim 47, wherein said condition is memory loss.

003300-782  
Attorney's Docket No.

50. (New) A method according to Claim 47, wherein said condition is caused by at least one factor selected from the group consisting of multiple sclerosis, hypoxic injury, ischemic injury, traumatic injury, Parkinson's disease, and demyelinating disorder.

51. (New) A method according to Claim 43, wherein said substance is administered by intravenous infusion, intramuscular injection or subcutaneous injection.

52. (New) A method according to Claim 43, wherein brain cells are removed from the patient after said administration, said brain cells then being propagated in vitro, followed by transplantation of the obtained cells back into the brain of a patient in need thereof.

53. (New) A method according to Claim 52, wherein an effective amount of growth hormone or a functionally equivalent analogue thereof is administered to said brain cells during in vitro propagation.

54. (New) A method of reducing the genesis of oligodendrocytes, neurons, astroglia cells from progenitor cells or stem cells in, or derived from, the central or peripheral nervous system in a patient, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally equivalent analogue thereof is administered to a patient in need thereof.

0985575-074304  
F00720-92555560  
A1 and

55. (New) A method according to Claim 54, wherein said substance is administration to the peripheral or central nervous system of said patient.

56. (New) A method according to Claim 54, wherein said substance is selected from the group consisting of negatively regulating growth hormone binding proteins, functionally equivalent analogous thereof, antibodies against growth hormone, biologically active growth hormone receptor inhibitors, and inhibitors of endogenous GH release.

57. (New) A method according to Claim 54, for treatment of a central nervous system injury.

58. (New) A method according to Claim 57, wherein said injury is the consequence of a factor selected from the group consisting of axonal damage caused by concussion, axonal damage caused by head trauma, axonal damage caused by small vessel disease in the CNS, damage to the spinal cord after disease or trauma.

Add B'

003300-782